Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation

about

Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation

Item

http://www.wikidata.org/entity/Q56993837

description

scientific article published on 23 November 2007

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в січні 2008

@uk

name

Evaluation of bone disease in multiple myeloma patients carrying the t

@nl

Evaluation of bone disease in ...... ;14) chromosomal translocation

@en

type

Item

label

Evaluation of bone disease in multiple myeloma patients carrying the t

@nl

Evaluation of bone disease in ...... ;14) chromosomal translocation

@en

prefLabel

Evaluation of bone disease in multiple myeloma patients carrying the t

@nl

Evaluation of bone disease in ...... ;14) chromosomal translocation

@en

P1476

Evaluation of bone disease in ...... ;14) chromosomal translocation

@en

P2093

Annamaria Brioli

http://www.w3.org/2001/XMLSchema#string

Carolina Terragna

http://www.w3.org/2001/XMLSchema#string

Elena Montanari

http://www.w3.org/2001/XMLSchema#string

Elena Zamagni

http://www.w3.org/2001/XMLSchema#string

Maria C Pallotti

http://www.w3.org/2001/XMLSchema#string

Matteo Renzulli

http://www.w3.org/2001/XMLSchema#string

Michela Ceccolini

http://www.w3.org/2001/XMLSchema#string

Michele Baccarani

http://www.w3.org/2001/XMLSchema#string

Paola Tacchetti

http://www.w3.org/2001/XMLSchema#string

Patrizia Tosi

http://www.w3.org/2001/XMLSchema#string

P2860

Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients

Chromosome translocations in multiple myeloma

Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma.

The molecular classification of multiple myeloma

Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy.

CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.

Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index.

Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer.

Clinical and biologic implications of recurrent genomic aberrations in myeloma.

First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma.

P304

31-36

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1600-0609.2007.00974.X

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Giulia Perrone

Nicoletta Testoni

Michele Cavo

P577

2007-11-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18036184

http://www.w3.org/2001/XMLSchema#string